$695 | Single User
$1395 | Global License

Physician Views: How do oncologists use companion diagnostics, what are the key challenges and which pharma companies are best at supporting them?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Oct 2013 | 70 | In Stock
Related Topics: Roche

Introduction

Scope


As exemplified by Roche's R&D presentation last week (see Spotlight On: Roche's R&D day – The key takeaways), the use of biomarkers to segment cancer patient populations – with the aim to both enhance the drug development process and the efficacy of resultant therapies – is set to play an integral role in how this disease area continues to develop.



There has already been notable commercial success with this approach and the use of companion diagnostics to identify which patients stand to benefit most from particular therapies - the best example probably being Roche's own HER2-positive breast cancer treatment Herceptin.



The Swiss company plays a prominent role in this approach – Roche being the global leader in both the oncology drug and diagnostic markets – but a biomarker approach to cancer drug development is now common place across the industry.



But what do physicians think of companion diagnostics and how they have evolved the treatment of cancer? The general sentiment suggests that they are a purely positive development, but do oncologists face particular challenges in using cancer treatments in conjunction with a companion diagnostic and what can be done to improve how these predictive tools can be used?


Puchase Reasons


This week's Physician Views poll asks oncologists based in the US and 5EU markets:


  • How many cancer patients they assess with a companion diagnostic prior to treatment?

  • How the role of a companion diagnostic impacts their uptake/usage of an associated cancer product?

  • What their biggest challenges are in using companion diagnostics and an associated cancer product?

  • What pharmaceutical manufacturers could provide to improve and enhance the experience of using companion diagnostics?

  • Which pharmaceutical companies provide the best support and most effective information regarding companion diagnostics and associated cancer treatments?
  • Table of Contents
    for Physician Views: How do oncologists use companion diagnostics, what are the key challenges and which pharma companies are best at supporting them? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    70 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: How do oncologists use companion diagnostics, what are the key challenges and which pharma companies are best at supporting them? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...